Aziyo Biologics Inc (AZYO) Peer Comparison
$1.64
$0.19
(13.10%)
As on 08-Nov-2023 09:30EDT
Market cap
$24 Mln
Revenue (TTM)
$42 Mln
P/E Ratio
--
P/B Ratio
13.3
Div. Yield
0 %
Edit
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
24 | 12,560 | 11,626 | 11,167 | 10,705 |
Revenue ($ Mln) |
42 | 1,505 | 6,164 | 617 | 785 |
Net Profit ($ Mln) |
-33.78 | 160.59 | 625.00 | -75.13 | 41.54 |
Net Margin (%) |
-80.17 | 10.67 | 5.41 | -12.18 | 5.29 |
RoE (%) |
-- | 10.86 | 11.84 | -9.26 | 1.97 |
Price to Earnings |
-- | 78.15 | 18.90 | -- | 263.44 |
Price-To-Book |
13.34 | 8.19 | 2.25 | 11.93 | 4.93 |
Income Statement ($ Mln)
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
42.14 | 847.13 | 5,215.00 | 516.41 | 801.54 |
|
Cost of Revenue
|
26.99 | 311.93 | 1,515.00 | 120.39 | 345.83 |
|
Gross Profit
|
19.22 | 535.21 | 3,700.00 | 396.02 | 455.71 |
|
Operating Expenses
|
37.10 | 529.13 | 3,250.00 | 563.97 | 231.04 |
|
Operating Profit (EBIT)
|
-26.51 | 6.08 | 450.00 | -167.94 | 224.67 |
|
Other Income
|
0.00 | -2.33 | -- | 6.45 | -4.37 |
|
Profit before Tax
|
-32.52 | 3.89 | 235.00 | -161.97 | 219.14 |
|
Provision for Tax
|
0.03 | 5.89 | 12.00 | 4.03 | 33.18 |
|
Profit after Tax (Net Income)
|
-33.78 | -2.00 | 223.00 | -166.00 | 185.96 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-7.97 | -2.00 | 223.00 | -166.00 | 185.96 |
Liabilities ($ Mln)
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-29.47 | 998.86 | 5,259.00 | 805.74 | 1,910.70 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
39.32 | 227.10 | 2,992.00 | 92.28 | 216.70 |
|
Current Liabilities
|
44.74 | 144.93 | 1,715.00 | 130.96 | 404.20 |
|
Total Liabilities
|
68.84 | 1,370.89 | 9,966.00 | 1,028.98 | 2,531.60 |
Assets ($ Mln)
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
15.45 | 615.19 | 6,110.00 | 393.95 | 1,533.48 |
|
Current Assets
|
39.13 | 755.70 | 3,856.00 | 635.04 | 998.12 |
|
Total Assets
|
68.84 | 1,370.89 | 9,966.00 | 1,028.98 | 2,531.60 |
|
Total Debt*
|
31.15 | 235.77 | 2,872.00 | 95.18 | 422.96 |
|
Net Current Assets
|
0.00 | 610.77 | 2,141.00 | 504.08 | 593.92 |
Cashflow ($ Mln)
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-21.43 | -55.66 | 468.00 | -33.61 | 172.08 |
|
Cash Flow from Investing Activities
|
-- | 54.79 | -472.00 | -350.89 | -233.24 |
|
Cash from Financing Activities
|
8.54 | 11.62 | -926.00 | 15.82 | -13.34 |
|
Net Cash Inflow / Outflow
|
-- | 10.75 | -- | -368.68 | -74.49 |
Ratios
Profitability Ratios
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-94.86 | -0.17 | 2.62 | -18.44 | 8.36 |
|
ROE (%)
|
-775.14 | -0.21 | 4.12 | -20.45 | 10.16 |
|
ROA (%)
|
-34.67 | -0.15 | 2.14 | -16.21 | 7.61 |
|
EBIT Margin (%)
|
-44.66 | -- | -- | -- | -- |
|
Net Margin (%)
|
-80.17 | -0.24 | 4.28 | -31.75 | 23.33 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-11.07 | 0.13 | 0.00 | 0.05 | 0.20 |
|
EBIT Growth (%)
|
39.40 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
7.50 | -176.32 | -57.44 | -185.11 | 44.95 |
|
EPS Growth (%)
|
25.98 | -1.73 | -0.57 | -1.78 | 0.47 |
|
Book Value Growth (%)
|
-121.51 | -- | -- | -- | -- |
Valuation Ratios
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.87 | -4,322.18 | 104.88 | -25.19 | 51.99 |
|
Price / Book Value
|
-12.22 | 8.66 | 4.45 | 5.19 | 5.06 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-3.55 | 290.39 | 22.53 | -29.94 | 34.14 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.24 | 0.55 | 0.12 | 0.22 |
|
Short term debt to equity ratio
|
-0.01 | 0.01 | 0.03 | 0.01 | 0.15 |
|
Current Ratio
|
0.87 | 5.21 | 2.25 | 4.85 | 2.47 |
|
Quick Ratio
|
0.73 | 2.91 | 0.96 | 4.23 | 1.88 |
|
Interest Coverage
|
-4.35 | 3.23 | 8.23 | -339.28 | 74.00 |
Operating Efficiency Ratios
| Aziyo Biologics Inc (AZYO) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | 10X Genomics Inc (TXG) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
6.84 | 24.01 | 19.69 | 20.18 | 14.50 |
|
Asset Turnover
|
0.43 | 0.65 | 0.50 | 0.50 | 0.33 |
|
Receivable days
|
98.91 | 72.72 | 69.97 | 67.00 | 53.24 |
|
Inventory Days
|
119.49 | 349.83 | 488.08 | 214.80 | 223.26 |
|
Payable days
|
23.83 | 23.48 | 249.77 | 59.09 | 33.67 |
|
Cash Conversion Cycle
|
194.57 | 399.07 | 308.28 | 222.72 | 242.83 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
